^
    Back
    Association details:
    Biomarker:CCNE1 amplification
    Cancer:Ovarian Cancer
    Drug:SNS-032 (CDK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

    Excerpt:
    OVCAR3, the only CCNE1-amplified cell line in this panel, displayed intermediate sensitivity for SNS032 and dinaciclib.
    DOI:
    10.18632/oncotarget.2673